Video: Potential AIDS vaccine targets blood, mucosal tissue

December 1st is the annual World AIDS Day, a perfect opportunity to look at how medical research is progressing to fight the disease.

HIV is still plaguing humanity with 35 million infected people worldwide. Antiretroviral drugs do slow down the progression of the disease, but at a high cost and with long-term toxicity. More than ever, the need for a vaccine is urgent.

A current European research project seeks to block the entry of HIV into cells at mucosal sites and in the blood. Why target mucosal sites? Because 90% of HIV infections happen via the sexual route. Obtaining an immune response at this gateway could therefore mean efficiently blocking the virus and prevent it from ever entering the body.

This video is not supported by your browser at this time.

A first clinical trial on humans has just finished to check for toxicity. In the next step, researchers will determine whether the blood and mucosal tissue of the volunteers produces the neutralizing antibodies after exposure to HIV in the lab.

Related Stories

The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites ...

(Medical Xpress)—A team of researchers with members from Europe and the U.S. has found that viral replication may not be the main reason that the HIV virus is able to persist in the cells of infected patients ...

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...

Long-term (24-month) supplementation with multivitamins plus selenium for human immunodeficiency virus (HIV)-infected patients in Botswana in the early stages of disease who had not received antiretroviral therapy delayed ...

A mutant of an immune cell protein called ADAP (adhesion and degranulation-promoting adaptor protein) is able to block infection by HIV-1 (human immunodeficiency virus 1), new University of Cambridge research reveals. The ...

Recommended for you

Thirty years ago today, on March 2, 1985, the Food and Drug Administration approved a new HIV test. It was the result of nine months of round-the-clock labor by dozens of scientists. Immediately adopted by ...

How much money would be saved if one high-risk person was prevented from contracting HIV in the United States? A new study led by a researcher at Weill Cornell Medical College and published online Feb. 24 in Medical Care, answer ...

Once HIV-1 has hijacked a host cell to make copies of its own RNA genome and viral proteins, it must assemble these components into new virus particles. The orchestration of this intricate assembly process falls to a viral ...

New research from the Gladstone Institutes for the first time provides strong evidence that HIV latency is controlled not by infected host cells, but by the virus itself. This fundamentally changes how scientists ...

Postoperative mortality rates were low among patients infected with the human immunodeficiency virus (HIV) who are receiving antiretroviral therapy (ART), and those mortality rates were influenced as much by age and poor ...

With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists ...

User comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.